Oct 14, 2022 7:00am EDT Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
Sep 21, 2022 7:00am EDT Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program
Sep 19, 2022 7:00am EDT Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
Sep 12, 2022 7:00am EDT Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study
Sep 08, 2022 7:00am EDT Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami
Sep 01, 2022 7:00am EDT Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Aug 23, 2022 7:15am EDT Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
Aug 03, 2022 7:07am EDT Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
